Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02679885 · ClinicalTrials.gov registry record
Teriflunomide Male Transmission Study
A clinical trial, sponsored by Griffin Hospital.
- Completed
- Registry status
- 20
- Enrollment target
NCT02679885: Completed study, sponsored by Griffin Hospital.
NCT02679885 is a clinical trial that has completed, run by Griffin Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02679885 has completed, sponsored by Griffin Hospital.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
It is known that teriflunomide, a treatment for relapsing forms of multiple sclerosis, can be found in low concentrations in semen. Because the drug has been associated with teratogenicity in laboratory animals, the question is raised as to whether the drug can be detected in female partners of sexually active males who are taking the drug to treat their multiple sclerosis.
Primary Outcome
single laboratory evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-09 |
What the finished NCT02679885 record still lists
NCT02679885 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02679885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02679885 about?
NCT02679885 is a clinical study titled "Teriflunomide Male Transmission Study". It is known that teriflunomide, a treatment for relapsing forms of multiple sclerosis, can be found in low concentrations in semen. Because the drug has been associated with teratogenicity in laboratory animals, the question is raised as to whether the drug can be detected in female partners of sexu...
What is the current status of trial NCT02679885?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2015-10. Estimated completion is 2018-09.
Who is sponsoring clinical trial NCT02679885?
This trial is sponsored by Griffin Hospital, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia